---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-121842"
form_type: "8-K"
ticker: null
cik: "0000827871"
company_name: "EAGLE PHARMACEUTICALS, INC."
filed_at: "2023-11-29T23:59:59+00:00"
generated_at: "2026-06-07T20:39:07.106237+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Eagle Pharmaceuticals CEO Scott Tarriff resigns; Chairman Michael Graves named Interim Executive Chairman

## Summary
- Scott Tarriff resigns as President, CEO, and Director effective Nov 27, 2023; will serve as consultant starting Jan 1, 2024.
- Michael Graves appointed Interim Executive Chairman and Interim Principal Executive Officer; CEO search initiated.
- Board reduced from seven to six members; committee assignments realigned.
- Tarriff receives severance: 18-month base salary lump sum, target bonus, COBRA for 18 months, and $20k/month consulting retainer.
- Equity vesting acceleration for time-vesting awards; performance-vesting 2021 PSUs remain eligible during consulting period.

## SEC filing metadata
- accession: 0001104659-23-121842
- form_type: 8-K
- cik: 0000827871
- company_name: EAGLE PHARMACEUTICALS, INC.
- filed_at: 2023-11-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/827871/000110465923121842/0001104659-23-121842-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/827871/000110465923121842/tm2331615d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-121842
- JSON: https://secwatch.observer/filing/0001104659-23-121842.json
- Plain text: https://secwatch.observer/filing/0001104659-23-121842.txt

## Key facts
- Executive change
  Scott Tarriff resigned as President, Chief Executive Officer and Director at EAGLE PHARMACEUTICALS, INC..
  - Action: resigned
  - Role: President, Chief Executive Officer and Director
  source text: On November 27, 2023, Scott Tarriff, President and Chief Executive Officer of Eagle Pharmaceuticals, Inc. (the “Company”), resigned and retired from his positions with the Company as President, Chief Executive Officer, Principal Executive Officer and Director on the Company’s Board of Directors (the “Board”), effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/827871/000110465923121842/0001104659-23-121842-index.htm
- Executive change
  Michael Graves was appointed as Interim Executive Chairman and Interim Principal Executive Officer at EAGLE PHARMACEUTICALS, INC..
  - Action: appointed
  - Role: Interim Executive Chairman and Interim Principal Executive Officer
  source text: Michael Graves, Chairman of the Board, was appointed Interim Executive Chairman of the Board and Interim Principal Executive Officer, effective immediately, until such time as a new Chief Executive Officer commences employment or such other date determined by the Board or upon his earlier resignation.
  evidence_url: https://www.sec.gov/Archives/edgar/data/827871/000110465923121842/0001104659-23-121842-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.